This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

BG Medicine Announces Availability Of Galectin-3 Testing Service Through Health Diagnostic Laboratory, Inc.

WALTHAM, Mass. and RICHMOND, Va., March 24, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

The BG Medicine Galectin-3 Test was recently cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure. Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death. Galectin-3 has been implicated in a variety of biological processes important in heart failure development and progression, including fibrosis. Progressive cardiac fibrosis interferes with the cardiac pump function and increases the risk of death.  

The collaboration between BG Medicine and HDL, Inc. provides physicians with convenient access to galectin-3 testing to complement the range of cardiovascular tests already offered by HDL, Inc.

"HDL, Inc. is providing a new model of laboratory testing services to over 5,000 physicians with an emphasis on markers related to cardiovascular disease," said Pieter Muntendam, MD, President and CEO of BG Medicine. "The cardiovascular focus of HDL, Inc. makes this an excellent partnership to bring our message of the importance of galectin-3 in cardiac disease to the growing number physicians served by HDL, Inc."

Heart failure is a serious medical condition characterized by the heart's inability to pump blood efficiently to meet the requirements of the body's other organs. According to the American Heart Association, heart failure affects an estimated 5.8 million Americans with 670,000 new diagnoses each year. The estimated direct and indirect cost of this condition in the US is $39.2 billion.  

"Galectin-3 further enhances our extensive cardiovascular disease offering," said Tonya Mallory, CEO and co-founder of Virginia-headquartered HDL, Inc. "Novel markers like galectin-3 are expected to enable a new medical model where physicians can triage patients not only based on their clinical status on the day of the visit, but also based on the type of underlying disease process and its prognostic implications." 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs